Many childhood brain tumors harbor potentially targetable gene mutations, according to a prospective single-institution study of more than 200 tumor samples, researchers reported in the journal Neuro-Oncology.
Researchers are reporting in the journal Cancer Research that they have identified a biomarker enzyme associated with aggressive glioma brain tumors. In addition, they have demonstrated potent efficacy in a mouse model of glioma for a small molecule inhibitor they recently developed.
A new study is suggesting that radiomic features subjected to machine learning algorithms may be able to identify imaging signatures that defined a subset of patients with recurrent glioblastoma who may gain the most benefit from antiangiogenic therapy.
First-line crizotinib therapy offered better intracranial disease control rate than chemotherapy in patients with ALK-positive non–small-cell lung cancer (NSCLC) and stable treated brain metastases.
Researchers at the University of Pittsburgh have developed a sequencing test to analyze a broad spectrum of genetic alterations in central nervous system (CNS) tumors.
The PD-1‒targeting drug nivolumab combined with stereotactic radiation may work synergistically and help improve overall survival while resulting in minimal neurotoxicity in brain metastatic melanoma patients.
Expression of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) is associated with poor glioblastoma outcomes.
HLA-A2-positive glioblastoma patients experienced more frequent immune responses to the dendritic-cell immunotherapy IDT-107, responses that may be associated with improved survival.
Early results from an ongoing trial suggest that pembrolizumab has promising activity in untreated melanoma patients with brain metastases.
A rare genetic mutation appears to extend survival among a subset of patients diagnosed with non-small cell lung cancer (NSCLC) brain metastases, and represents a promising biomarker that can help guide radiotherapy planning.